Header Logo

Hajime Senjo

TitlePostdoc Fellows and Associates
InstitutionBaylor College of Medicine
DepartmentPostDoc
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yamaguchi Y, Senjo H, Taniguchi Y, Aiba M, Miyagishima T. Efgartigimod as a Steroid-sparing Therapy for Evans Syndrome: A Case Report. Intern Med. 2026 Jun 11. PMID: 42270395.
      Citations:    
    2. Kanaya M, Onozawa M, Matsukawa T, Miyashita N, Fujii F, Yoshida S, Nagai J, Aiba M, Hidaka D, Hashiguchi J, Senjo H, Igarashi T, Chiba M, Yamamoto S, Shimizu T, Ishio T, Yokoyama S, Ebata K, Iyama S, Oyake T, Kondo T, Teshima T. Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net. Blood Cancer J. 2025 Jul 03; 15(1):118. PMID: 40610408; PMCID: PMC12229622.
      Citations: 5     Fields:    
    3. Senjo H, Hashimoto D. [Donor T cell exhaustion and immune tolerance after allogeneic hematopoietic cell transplantation]. Rinsho Ketsueki. 2025; 66(5):339-347. PMID: 40467463.
      Citations:    Fields:    Translation:HumansAnimalsCells
    4. Izumiyama K, Inao T, Goto H, Harada S, Senjo H, Suto K, Hashiguchi J, Ogasawara R, Saga T, Igarashi T, Wakasa K, Kasahara I, Takeda Y, Yamaguchi K, Shigematsu A, Takahata M, Fujimoto K, Haseyama Y, Nagashima T, Sakai H, Kakinoki Y, Kurosawa M, Yokota I, Teshima T. Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group. Haematologica. 2024 Nov 01; 109(11):3631-3640. PMID: 38867578; PMCID: PMC11532691.
      Citations:    
    5. Senjo H, Hashimoto D, Teshima T. Calcineurin inhibitor blocks tolerance by suppressing donor T cell terminal exhaustion after allogeneic hematopoietic cell transplantation. J Clin Invest. 2024 Oct 15; 134(20). PMID: 39403931; PMCID: PMC11473144.
      Citations:    
    6. Hasegawa Y, Hashimoto D, Zhang Z, Miyajima T, Saito Y, Li W, Kikuchi R, Senjo H, Sekiguchi T, Tateno T, Chen X, Yokoyama E, Takahashi S, Ohigashi H, Ara T, Hayase E, Yokota I, Teshima T. GVHD targets organoid-forming bile duct stem cells in a TGF-?-dependent manner. Blood. 2024 08 22; 144(8):904-913. PMID: 38905638.
      Citations: 7     Fields:    Translation:AnimalsCells
    7. Goto H, Sugita J, Hasegawa Y, Hayasaka K, Sunagoya K, Hatase R, Nishida M, Ichihashi Y, Odera M, Senjo H, Yokoyama S, Ara T, Shiratori S, Endo T, Hino M, Maeda Y, Sawa M, Sato N, Teshima T. Efficacy and Safety of Single-dose Pegfilgrastim for CD34 + Cell Mobilization in Healthy Volunteers: A Phase 2 Study. Transplantation. 2024 04 01; 108(4):996-1003. PMID: 38012835; PMCID: PMC10962423.
      Citations:    
    8. Morishima Y, Kawabori M, Yamazaki K, Takamiya S, Yamaguchi S, Nakahara Y, Senjo H, Hashimoto D, Masuda S, Fujioka Y, Ohba Y, Mizuno Y, Kuge Y, Fujimura M. Intravenous Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Spinal Cord Injury by Regulating Neutrophil Extracellular Trap Formation through Exosomal miR-125a-3p. Int J Mol Sci. 2024 Feb 18; 25(4). PMID: 38397083; PMCID: PMC10889446.
      Citations:    
    9. Senjo H, Harada S, Kubota SI, Tanaka Y, Tateno T, Zhang Z, Okada S, Chen X, Kikuchi R, Miyashita N, Onozawa M, Goto H, Endo T, Hasegawa Y, Ohigashi H, Ara T, Hasegawa Y, Murakami M, Teshima T, Hashimoto D. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT. Blood. 2023 08 03; 142(5):477-492. PMID: 37216687.
      Citations:    
    10. Mori A, Onozawa M, Kobayashi M, Tsukamoto S, Senjo H, Ishio T, Yokoyama E, Kanaya M, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies. Cancer Med. 2023 08; 12(16):16881-16888. PMID: 37409608; PMCID: PMC10501249.
      Citations:    
    11. Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. Int J Clin Oncol. 2023 Jun; 28(6):816-826. PMID: 37071252.
      Citations:    
    12. Kobayashi M, Mori A, Onozawa M, Tsukamoto S, Senjo H, Ishio T, Yokoyama E, Kanaya M, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms. Ann Hematol. 2023 Apr; 102(4):819-827. PMID: 36862167; PMCID: PMC9978274.
      Citations:    
    13. Mori A, Onozawa M, Kobayashi M, Tsukamoto S, Senjo H, Ishio T, Yokoyama E, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia. Br J Haematol. 2023 03; 200(6):717-721. PMID: 36442510; PMCID: PMC9877767.
      Citations:    
    14. Chen X, Hashimoto D, Ebata K, Takahashi S, Shimizu Y, Shinozaki R, Hasegawa Y, Kikuchi R, Senjo H, Yoneda K, Zhang Z, Harada S, Hayase E, Ara T, Ohigashi H, Iwakura Y, Nakamura K, Ayabe T, Teshima T. Reactive granulopoiesis depends on T-cell production of IL-17A and neutropenia-associated alteration of gut microbiota. Proc Natl Acad Sci U S A. 2022 11 29; 119(48):e2211230119. PMID: 36409919; PMCID: PMC9860329.
      Citations:    
    15. Senjo H, Onozawa M, Hidaka D, Yokoyama S, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Hashimoto D, Kondo T, Teshima T. High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia. Sci Rep. 2022 05 25; 12(1):8885. PMID: 35614177; PMCID: PMC9133033.
      Citations:    
    16. Harada S, Onozawa M, Hidaka D, Yokoyama S, Senjo H, Takahashi S, Ogasawara R, Kanaya M, Mori A, Ota S, Kondo T, Teshima T. Dynamic change in peripheral blood WT1 mRNA levels within three cycles of azacitidine predict treatment response in patients with high-risk myelodysplastic syndromes. Ann Hematol. 2022 Jun; 101(6):1239-1250. PMID: 35257209.
      Citations:    
    17. Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X, Yoneda K, Sekiguchi T, Kawase T, Tsuzuki H, Ishio T, Ara T, Ohigashi H, Nakagawa M, Teshima T. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2022 05; 57(5):775-780. PMID: 35228711.
      Citations:    
    18. Senjo H, Onozawa M, Hidaka D, Yokoyama S, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Hashimoto D, Kondo T, Teshima T. A novel nutritional index "simplified CONUT" and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemia. Sci Rep. 2020 11 10; 10(1):19400. PMID: 33173122; PMCID: PMC7655799.
      Citations:    
    19. de Leon MRP, Takahashi S, Onozawa M, Ito M, Nakano M, Senjo H, Chiba M, Ohigashi H, Yokoyama E, Sugita J, Hashimoto D, Teshima T. Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody. Blood Cell Ther. 2020 Nov 25; 3(4):74-77. PMID: 36711008; PMCID: PMC9847262.
      Citations:    
    20. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, Fukumoto T, Sato K, Oguri S, Taki K, Senjo H, Sugita J, Hayasaka K, Konno S, Nishida M, Teshima T. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. J Infect. 2020 08; 81(2):e145-e147. PMID: 32504740; PMCID: PMC7270800.
      Citations:    
    21. Senjo H, Hirata K, Izumiyama K, Minauchi K, Tsukamoto E, Itoh K, Kanaya M, Mori A, Ota S, Hashimoto D, Teshima T, North Japan Hematology Study Group. High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma. Blood Adv. 2020 05 26; 4(10):2286-2296. PMID: 32453838; PMCID: PMC7252551.
      Citations:    
    22. Senjo H, Hashimoto D. Unusual computed tomography findings of acute eosinophilic pneumonia after cord blood transplantation. Int J Hematol. 2019 Oct; 110(4):387-388. PMID: 31325151.
      Citations:    
    23. Senjo H, Kanaya M, Izumiyama K, Minauchi K, Hirata K, Mori A, Saito M, Tanaka M, Iijima H, Tsukamoto E, Itoh K, Ota S, Morioka M, Hashimoto D, Teshima T, North Japan Hematology Study Group (NJHSG). Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18 F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma. Cancer Med. 2019 03; 8(3):953-962. PMID: 30790452; PMCID: PMC6434200.
      Citations:    
    24. Saito M, Senjo H, Kanaya M, Izumiyama K, Mori A, Tanaka M, Morioka M, Ieko M. Acquired hemophilia A developing cerebral infarction 36 days after the frequent administration of bypass hemostatic agents. Hematol Rep. 2018 Sep 05; 10(3):7453. PMID: 30283617; PMCID: PMC6151351.
      Citations:    
    25. Senjo H, Higuchi T, Okada S, Takahashi O. Hyperferritinemia: causes and significance in a general hospital. Hematology. 2018 Dec; 23(10):817-822. PMID: 29914346.
      Citations:    
    26. Senjo H, Higuchi T, Morimoto M, Koyamada R, Yanaoka C, Okada S. Simultaneous Presentation of Giant Cell Arteritis and Myelodysplastic Syndrome in an Elderly Japanese Man. Intern Med. 2018 Oct 01; 57(19):2889-2893. PMID: 29780154; PMCID: PMC6207824.
      Citations:    
    27. Saito M, Senjo H, Kanaya M, Izumiyama K, Mori A, Tanaka M, Morioka M, Miyashita K, Ishida Y. Management consideration for patient with a large solitary fibrous tumor occupying the infratemporal fossa: A case report. Mol Clin Oncol. 2018 04; 8(4):544-548. PMID: 29556387; PMCID: PMC5844077.
      Citations:    
    28. Saito M, Senjo H, Kanaya M, Izumiyama K, Mori A, Tanaka M, Morioka M, Miyashita K, Ishida Y. Late duodenal metastasis from renal cell carcinoma with newly developed malignant lymphoma: A case report. Mol Clin Oncol. 2018 04; 8(4):549-552. PMID: 29556388; PMCID: PMC5844005.
      Citations:    
    29. Senjo H, Mori A, Kanaya M, Izumiyama K, Okada K, Takeyabu K, Tobioka H, Saito M, Tanaka M, Teshima T, Morioka M. [Pyothorax-associated lymphoma with the expression of Epstein-Barr virus latent genes]. Nihon Ronen Igakkai Zasshi. 2018; 55(1):143-147. PMID: 29503358.
      Citations:    
    Senjo's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (115)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Same Department Expand Description
    Explore
    _